Theaflavin

Theaflavin

SCHEMBL29779739

O=c1c(O)cc([C@H]2Oc3cc(O)cc(O)c3C[C@H]2O)cc2c([C@H]3Oc4cc(O)cc(O)c4C[C@H]3O)cc(O)c(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 1.00
MAPT P10636 5/20 1.00
APEX1 P27695 5/20 1.00
RECQL P46063 5/20 1.00
HSD17B10 Q99714 5/20 1.00
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
HPGD P15428 4/20 1.00
ALOX15 P16050 4/20 1.00
TDP1 Q9NUW8 4/20 1.00
CYP3A4 P08684 4/20 1.00
BLM P54132 3/20 1.00
USP2 O75604 2/20 1.00
THRB P10828 2/20 1.00
CASP1 P29466 2/20 1.00
GALK1 P51570 2/20 1.00
BCL2 P10415 3/20 0.81
CYP17A1 P05093 1/20 0.81
CDK2 P24941 1/20 0.81
BACE1 P56817 6/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Theaflavin SCHEMBL4379393 1.00 KDM4E (1.00) KDM4EMAPTAPEX1RECQLHSD17B10
Theaflavin SCHEMBL29373772 1.00 KDM4E (1.00) KDM4EMAPTAPEX1RECQLHSD17B10
Theaflavin SCHEMBL13530895 1.00 KDM4E (1.00) KDM4EMAPTAPEX1RECQLHSD17B10
Theaflavin SCHEMBL18346731 1.00 KDM4E (1.00) KDM4EMAPTAPEX1RECQLHSD17B10
Theaflavin SCHEMBL13300889 1.00 KDM4E (1.00) KDM4EMAPTAPEX1RECQLHSD17B10
Theaflavin SCHEMBL12658747 1.00 KDM4E (1.00) KDM4EMAPTAPEX1RECQLHSD17B10
Theaflavin SCHEMBL19551 1.00 KDM4E (1.00) KDM4EMAPTAPEX1RECQLHSD17B10
Theaflavin SCHEMBL14847403 1.00 KDM4E (1.00) KDM4EMAPTAPEX1RECQLHSD17B10
Theaflavin SCHEMBL17430775 1.00 KDM4E (1.00) KDM4EMAPTAPEX1RECQLHSD17B10
Theaflavin SCHEMBL12792925 1.00 KDM4E (1.00) KDM4EMAPTAPEX1RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4132502-A1 A PHARMACEUTICAL COMPOSITION AND ITS USE TO INHIBIT MEMBRANE ACE2 EXPRESSION Rath, Matthias W. (US) 2023-02-15 EP claimed
US-20260034137-A1 Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity JUVN3 HOLDINGS, LLC (US) 2026-02-05 US disclosed
US-20260034152-A1 Influx Vitamins and Drinks, with Zinc Ionophoric Influx BLACK STEPHEN (US) 2026-02-05 US disclosed
EP-4408435-B1 COMPOSITION COMPRISING HESPERIDIN, CITRAL AND SODIUM ALGINATE AS A FILM-FORMING SUBSTANCE FOR PROPHYLAXIS OF INFECTIONS MVS PHARMA GMBH (DE) 2025-08-13 EP disclosed
EP-4452323-A1 COMPOSITIONS COMPRISING STEROL-AMINO-PHOSPHATE COMPOUNDS AND METHODS OF MAKING AND USE THEREOF Ohio State Innovation Foundation (US) 2024-10-30 EP disclosed
EP-4408435-A1 COMPOSITION COMPRISING HESPERIDIN, CITRAL AND A FILM-FORMING SUBSTANCE FOR PROPHYLAXIS OF INFECTIONS MVS Pharma GmbH (DE) 2024-08-07 EP disclosed
WO-2023212607-A1 INFLUX VITAMINS AND DRINKS, WITH ZINC IONOPHORIC INFLUX BLACK STEPHEN (US) 2023-11-02 WO disclosed
WO-2023122075-A1 COMPOSITIONS COMPRISING STEROL-AMINO-PHOSPHATE COMPOUNDS AND METHODS OF MAKING AND USE THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2023-06-29 WO disclosed
US-20230149412-A1 Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity JUVN3 HOLDINGS, LLC (US) 2023-05-18 US disclosed
US-20230149488-A1 Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity JUVN3 HOLDINGS, LLC (US) 2023-05-18 US disclosed
WO-2023052310-A1 COMPOSITION COMPRISING HESPERIDIN, CITRAL AND A FILM-FORMING SUBSTANCE FOR PROPHYLAXIS OF INFECTIONS MSV PHARMA GMBH (DE) 2023-04-06 WO disclosed
EP-4159208-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS OF AN INFECTION MVS Pharma GmbH (DE) 2023-04-05 EP disclosed
EP-4132502-A1 A PHARMACEUTICAL COMPOSITION AND ITS USE TO INHIBIT MEMBRANE ACE2 EXPRESSION Rath, Matthias W. (US) 2023-02-15 EP disclosed
US-20230025435-A1 COMPOSITIONS AND METHODS FOR INCREASING CELLULAR VITALITY AND LONGEVITY AND DECREASING MOLECULAR AGEING JUVN3 HOLDINGS, LLC (US) 2023-01-26 US disclosed
US-20220304976-A1 Method of simultaneously treating viral disease caused coronavirus, its variants and mutants using a pharmaceutical micronutrient composition Rath, Matthias W (US) 2022-09-29 US disclosed
US-11419847-B2 Pharmaceutical micronutrient composition and its use to simultaneously inhibit multiple cellular mechanisms of infectivity caused by coronavirus, its variants and mutants Rath, Matthias W. (US) 2022-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034137-A1 Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity TFAM, POT1, CLPX KDM4E 1627/4885MAPT 659/4885APEX1 179/4885
US-20260034152-A1 Influx Vitamins and Drinks, with Zinc Ionophoric Influx KCNN3, VDR, KCNN2 KDM4E 3131/4885MAPT 3544/4885APEX1 4465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.